Cancerous disease modifying antibodies
View Patent ↗The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
1. An isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02.
2. A humanized version of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02.
3. A chimeric version of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02.
4. The isolated hybridoma cell line deposited with the IDAC as accession number 180706-02.
5. An antigen binding fragment of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02.
6. An antigen binding fragment of a humanized version of the antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02.
7. An antigen binding fragment of a chimeric version of the antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02.
8. The isolated antibody of any one of claim 1 , 2 , or 3 conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells.
9. A composition, comprising in combination:
an antibody of any one of claim 1 , 2 , or 3 ; and
a pharmaceutically acceptable carrier.
10. A composition, comprising in combination:
the isolated antibody of any one of claim 1 , 2 , or 3 conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells; and
a pharmaceutically acceptable carrier.
11. The antigen binding fragment of any one of claim 5 , 6 , or 7 conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells.
12. A composition, comprising in combination:
an antigen binding fragment of any one of claim 5 , 6 , or 7 ; and
a pharmaceutically acceptable carrier.
13. A composition, comprising in combination:
the antigen binding fragment of any one of claim 5 , 6 , or 7 conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells; and
a pharmaceutically acceptable carrier.